GranuFlo/NaturaLyte Lawsuit Alleges Wrongful Death from Dialysis Products

By TopClassActions | October 10, 2013

Category: Pharmaceuticals

By Shawn Coates

Kidney Dialysis Lawsuit A new lawsuit filed against Fresenius Medical Care alleges that Clarence Bell Jr., a resident of Jefferson County, Mississippi, went through dialysis treatments, which included the use of GranuFlo and NaturaLyte. Shortly after his dialysis treatments, Clarence suffered from adverse cardiovascular events that caused him to die on March 1, 2012. The plaintiff filed a wrongful death lawsuit on behalf of Bell, claiming that Bell’s death was caused by GranuFlo and NaturaLyte.

The plaintiff believes that Bell’s individual healthcare providers did not know the risks associated with the GranuFlo and NaturaLyte products in the dialysis process. The GranuFlo lawsuit claims that, had Clarence actually known about any risks associated with the dialysis treatment, he would not have chosen the treatment and might still be alive to this day. Even the healthcare providers claim that they would not have supported such a procedure had they been aware of the risks involved.

Now, action is being taken against Fresenius Medical Care, the maker of GranuFlo and NaturaLyte, on allegations claiming that their dialysis products cause an increased risk of death with injuries including cardiovascular injuries, heart attack, stroke, and cardiopulmonary heart arrest.

Concealing Risks

Fresenius is the world’s largest medical care corporation that specializes in dialysis treatment. According to the GranuFlo lawsuit, at all times during Bell’s dialysis procedures was Fresenius responsible for the manufacturing, marketing and distribution of the GranuFlo and NaturaLyte liquids.

Further, “an internal memo from Fresenius published in November of 2011 indicated that Fresenius had knowledge that there was a significant risk of cardiac arrest and death during hemodialysis treatments using GranuFlo and NaturaLyte,” the lawsuit states.

In addition, it is alleged that multiple executives and officers within the company had previous knowledge of possible side effects, but decided against informing the U.S. Food & Drug Administration (FDA) or their consumers.

Failure to Disclose

Eventually, the FDA conducted an inquiry into the risks associated with GranuFlo and NaturaLyte. In response, Fresenius delivered a two page memo that only addressed a portion of the alleged risks. The alleged internal memo from within their corporation contained far more detailed, honest information than the memo that was delivered to the FDA. Fresenius, as a company, is required to disclose any and all information relating to a product, especially when lives are on the line.

The GranuFlo/NaturaLyte lawsuit is Henry Bell on behalf of Clarence Bell v. Fresenius USA Inc., Case No. 1:13-cv-12358-DPW, in the Circuit Court of Jefferson County, Mississippi.

Take Action Against Fresenius Medical Care Now

If you or someone you know someone have been the victim of an overdose of alkali or bicarbonate due to the use of GranuFlo or NaturaLyte during dialysis treatment, you may be eligible to join ongoing GranuFlo lawsuits and investigations. You can get more information by visiting the Kidney Dialysis Heart Attack, GranuFlo & NaturaLyte Recall Class Action Lawsuit Settlement Investigation. Here, you can find out more details about the investigation and the GranuFlo side effects that prompted the investigations and lawsuits in the first place.

All medical device, dangerous drug and medical class action and lawsuit news updates are listed in the Drug and Medical Device section of Top Class Actions.

LEGAL INFORMATION IS NOT LEGAL ADVICE
Top Class Actions Legal Statement

Various Trademarks held by their respective owners.